| Pair Name | Tiliroside, Anti-MUC1 antibody | ||
| Phytochemical Name | Tiliroside (PubChem CID: 5320686 ) | ||
| Anticancer drug Name | Anti-MUC1 antibody (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Tiliroside, Anti-MUC1 antibody | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | NFKB1 | hsa4790 |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| Result | The combined action of anti-MUC1 and tiliroside was more effective in comparison with monotherapy in the case of C1GalT1, ST3GalT1, FUT4, Gal-3, NF-κB, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression. The results of our study indicate that applied combined therapy may be a promising anti-gastric cancer strategy. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells. Int J Mol Sci. 2023 Aug 22;24(17):13036. doi: 10.3390/ijms241713036. | Click |
